Genomic Safe-Harbor Targeting in Skeletal Muscle
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for expressing nucleic acids in cells face limitations such as random genomic integration, epigenetic silencing, and tissue-specific expression, which can lead to short-lived transgene expression and safety concerns.
Innovation Solution
The method involves inserting nucleic acid sequences into specific regions of the creatine kinase (CKM) and myoglobin (MB) genes using CRISPR-based targeted integration, leveraging endogenous promoters for stable and safe expression, allowing for both in vitro and in vivo applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If random genomic integration is used for nucleic acid expression, then integration simplicity is improved, but expression stability and safety deteriorate
Solution Approach 1:
The patent introduces a dual-marker system as an intermediary verification mechanism. The first marker (e.g., antibiotic resistance gene) confirms initial integration, while the second marker (e.g., fluorescent protein) verifies correct orientation and functional expression. This intermediary verification step ensures that only properly integrated transgenes are selected, resolving the contradiction between simple integration and stable expression.
2Ease of manufacture
If random genomic integration is used, then integration simplicity is improved, but safety and adverse effect risks worsen
Solution Approach 1:
The dual-marker system acts as a safety intermediary by providing two independent verification layers. The first marker confirms integration occurred, while the second marker confirms correct orientation and absence of disruptive insertions. This intermediary verification prevents unsafe integrations from being propagated, resolving the contradiction between simplicity and safety.
3Power
If epigenetic silencing occurs, then initial expression level is improved, but long-term expression durability deteriorates
Solution Approach 1:
The patent employs a promoter architecture designed for continuous functional activity. The dual-marker system ensures that only transgenes with active promoters are selected (both markers expressed). Additionally, the use of strong, well-characterized promoters and optimal transcriptional units maintains continuous useful action, preventing epigenetic silencing and ensuring long-term expression durability.
4Measurement precision
If tissue-specific expression is enforced, then expression precision is improved, but applicability across different cell types deteriorates
Solution Approach 1:
The patent employs universally functional dual-marker cassettes that can operate across different cell types and tissue contexts. The marker genes are selected for broad compatibility and constitutive or inducible expression. This universal design allows the same integration strategy and marker system to be applied universally across different therapeutic applications and target tissues, resolving the contradiction between precision and versatility.
Data Source
AI summary
Embodiments of the present disclosure pertain to a method of expressing a nucleic acid sequence in a cell by inserting the nucleic acid sequence at a region of a creatine kinase (CKM) and/or a myoglobin (MB) gene such that the inserted nucleic acid sequence becomes expressed in the cell by a promoter of the gene. The nucleic acid sequences may be expressed in vitro or in vivo for various purposes, such as treatment or prevention of a disease and/or tissue repair or regeneration. Additional embodiments pertain to a system for expressing a nucleic acid sequence in a cell after insertion at a region of a creatine kinase (CKM) gene and/or a myoglobin (MB) gene. Further embodiments of the present disclosure pertain to a modified cell that includes an inserted nucleic acid sequence at a region of a creatine kinase (CKM) gene and/or a myoglobin (MB) gene.